Epigenetic therapy as a novel approach in hepatocellular carcinoma

Ioannis Anestopoulos, Georgia Persephoni Voulgaridou, Alexandros G. Georgakilas, Rodrigo Franco-Cruz, Aglaia Pappa, Mihalis I. Panayiotidis

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is the most common type of liver malignancy and one with high fatality. Its 5-year survival rate remains low and thus, there is a need for improvement of current treatment strategies as well as development of novel targeted methodologies in order to optimize existing therapeutic protocols. To this end, only recently, it was discovered that its pathophysiology also involves epigenetic alterations in DNA methylation, histone modifications and/or non-coding microRNA patterns. Unlike genetic events, epigenetic alterations are reversible and thus potentially considered to be an alternative option in cancer treatment protocols. In this review, we describe the general characteristics and resulted major alterations of the epigenetic machinery as well as current state of progress of epigenetic therapy (via different single or combinatorial experimental approaches) in HCC.

Original languageEnglish (US)
Pages (from-to)103-119
Number of pages17
JournalPharmacology and Therapeutics
Volume145
DOIs
StatePublished - Jan 1 2015

Fingerprint

Epigenomics
Hepatocellular Carcinoma
Antineoplastic Protocols
Histone Code
DNA Methylation
Therapeutics
MicroRNAs
Liver
Neoplasms

Keywords

  • DNMT inhibitors
  • Epigenetic modifications
  • Epigenetic therapy
  • HDAC inhibitors
  • Hepatocellular carcinoma
  • Natural products

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Anestopoulos, I., Voulgaridou, G. P., Georgakilas, A. G., Franco-Cruz, R., Pappa, A., & Panayiotidis, M. I. (2015). Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacology and Therapeutics, 145, 103-119. https://doi.org/10.1016/j.pharmthera.2014.09.005

Epigenetic therapy as a novel approach in hepatocellular carcinoma. / Anestopoulos, Ioannis; Voulgaridou, Georgia Persephoni; Georgakilas, Alexandros G.; Franco-Cruz, Rodrigo; Pappa, Aglaia; Panayiotidis, Mihalis I.

In: Pharmacology and Therapeutics, Vol. 145, 01.01.2015, p. 103-119.

Research output: Contribution to journalReview article

Anestopoulos, I, Voulgaridou, GP, Georgakilas, AG, Franco-Cruz, R, Pappa, A & Panayiotidis, MI 2015, 'Epigenetic therapy as a novel approach in hepatocellular carcinoma', Pharmacology and Therapeutics, vol. 145, pp. 103-119. https://doi.org/10.1016/j.pharmthera.2014.09.005
Anestopoulos, Ioannis ; Voulgaridou, Georgia Persephoni ; Georgakilas, Alexandros G. ; Franco-Cruz, Rodrigo ; Pappa, Aglaia ; Panayiotidis, Mihalis I. / Epigenetic therapy as a novel approach in hepatocellular carcinoma. In: Pharmacology and Therapeutics. 2015 ; Vol. 145. pp. 103-119.
@article{8d1f875550bf4b8b8d67313aee4c66e9,
title = "Epigenetic therapy as a novel approach in hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is the most common type of liver malignancy and one with high fatality. Its 5-year survival rate remains low and thus, there is a need for improvement of current treatment strategies as well as development of novel targeted methodologies in order to optimize existing therapeutic protocols. To this end, only recently, it was discovered that its pathophysiology also involves epigenetic alterations in DNA methylation, histone modifications and/or non-coding microRNA patterns. Unlike genetic events, epigenetic alterations are reversible and thus potentially considered to be an alternative option in cancer treatment protocols. In this review, we describe the general characteristics and resulted major alterations of the epigenetic machinery as well as current state of progress of epigenetic therapy (via different single or combinatorial experimental approaches) in HCC.",
keywords = "DNMT inhibitors, Epigenetic modifications, Epigenetic therapy, HDAC inhibitors, Hepatocellular carcinoma, Natural products",
author = "Ioannis Anestopoulos and Voulgaridou, {Georgia Persephoni} and Georgakilas, {Alexandros G.} and Rodrigo Franco-Cruz and Aglaia Pappa and Panayiotidis, {Mihalis I.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.pharmthera.2014.09.005",
language = "English (US)",
volume = "145",
pages = "103--119",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Epigenetic therapy as a novel approach in hepatocellular carcinoma

AU - Anestopoulos, Ioannis

AU - Voulgaridou, Georgia Persephoni

AU - Georgakilas, Alexandros G.

AU - Franco-Cruz, Rodrigo

AU - Pappa, Aglaia

AU - Panayiotidis, Mihalis I.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Hepatocellular carcinoma (HCC) is the most common type of liver malignancy and one with high fatality. Its 5-year survival rate remains low and thus, there is a need for improvement of current treatment strategies as well as development of novel targeted methodologies in order to optimize existing therapeutic protocols. To this end, only recently, it was discovered that its pathophysiology also involves epigenetic alterations in DNA methylation, histone modifications and/or non-coding microRNA patterns. Unlike genetic events, epigenetic alterations are reversible and thus potentially considered to be an alternative option in cancer treatment protocols. In this review, we describe the general characteristics and resulted major alterations of the epigenetic machinery as well as current state of progress of epigenetic therapy (via different single or combinatorial experimental approaches) in HCC.

AB - Hepatocellular carcinoma (HCC) is the most common type of liver malignancy and one with high fatality. Its 5-year survival rate remains low and thus, there is a need for improvement of current treatment strategies as well as development of novel targeted methodologies in order to optimize existing therapeutic protocols. To this end, only recently, it was discovered that its pathophysiology also involves epigenetic alterations in DNA methylation, histone modifications and/or non-coding microRNA patterns. Unlike genetic events, epigenetic alterations are reversible and thus potentially considered to be an alternative option in cancer treatment protocols. In this review, we describe the general characteristics and resulted major alterations of the epigenetic machinery as well as current state of progress of epigenetic therapy (via different single or combinatorial experimental approaches) in HCC.

KW - DNMT inhibitors

KW - Epigenetic modifications

KW - Epigenetic therapy

KW - HDAC inhibitors

KW - Hepatocellular carcinoma

KW - Natural products

UR - http://www.scopus.com/inward/record.url?scp=84918778600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918778600&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2014.09.005

DO - 10.1016/j.pharmthera.2014.09.005

M3 - Review article

VL - 145

SP - 103

EP - 119

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -